Antiplatelet Therapy in DVT

1. Acute DVT treatment - anticoagulation, not antiplatelets

• Initiation (5-21 days): parenteral or high-dose oral anticoagulant (LMWH, UFH, fondaparinux, or a DOAC)
• Treatment phase (~12 weeks/3 months): standard-dose anticoagulation
• Extended phase: ongoing anticoagulation (full or reduced dose) if recurrence risk is high

2. Extended secondary prevention (after completing anticoagulation)

• WARFASA and ASPIRE trials (pooled/INSPIRE analysis) showed low-dose aspirin reduces recurrent VTE by roughly 30-35% versus placebo after a completed anticoagulation course, with a favorable bleeding profile.
• However, head-to-head data (EINSTEIN CHOICE trial - rivaroxaban or aspirin for extended treatment of VTE, referenced in the same texts) showed rivaroxaban (even at low dose) was substantially more effective than aspirin for extended prevention, with similar bleeding rates. This established DOACs as preferred over aspirin when extended anticoagulation is otherwise appropriate.
• Aspirin is therefore reserved for patients who decline or cannot tolerate continued anticoagulation but still want some protection during the extended phase.

3. VTE prophylaxis after orthopedic surgery (prevention, not treatment of established DVT)

Practical summary

1. Acute DVT treatment: aspirin has no role

• Initiation (5-21 days): parenteral or high-dose oral anticoagulant
• Treatment phase (~3 months): standard-dose anticoagulant (LMWH, fondaparinux, UFH, a DOAC, or warfarin)
• Extended phase: continued anticoagulation if recurrence risk remains high

2. Where aspirin actually matters: extended secondary prevention

• WARFASA and ASPIRE trials showed low-dose aspirin cuts recurrent VTE by roughly 30-35% versus placebo after finishing anticoagulation.
• EINSTEIN CHOICE trial (rivaroxaban vs. aspirin for extended treatment) found low-dose rivaroxaban clearly more effective than aspirin for extended prevention, with similar bleeding risk - so DOACs are preferred whenever continued anticoagulation is feasible. Aspirin is the second-line/fallback choice.
• A 2025 meta-analysis and trial sequential analysis (PMID: 40382433) reconfirms aspirin's modest benefit over placebo for extended prevention, but does not change its inferiority to anticoagulants.

3. Prophylaxis after orthopedic surgery (preventing a first DVT, not treating one)

• 2026 umbrella review (PMID: 40513910) and a 2024 meta-analysis (PMID: 39052442) both find aspirin comparably effective to other anticoagulants for VTE prevention after hip/knee arthroplasty or fracture fixation, with a better bleeding profile.

Summary table

Enoxaparin + Aspirin Together in DVT

Why they'd be combined

• Recent coronary stent or ACS
• Established coronary/peripheral artery disease
• Mechanical heart valve requiring an antiplatelet + anticoagulant regimen

The tradeoff: increased bleeding risk

• "Concomitant antiplatelet agents" are consistently listed as a factor that increases bleeding risk when combined with anticoagulants (LMWH, DOACs, or warfarin) - Goodman & Gilman's Pharmacological Basis of Therapeutics; Morgan and Mikhail's Clinical Anesthesiology.
• Morgan and Mikhail's notes that serious bleeding events with perioperative LMWH frequently involved patients also on concomitant antiplatelet medication.
• Rheumatology (Elsevier) similarly flags concomitant antiplatelet use as a risk multiplier for bleeding complications.

Practical approach when both are indicated

1. Confirm aspirin has its own independent, ongoing indication (not being given "for the DVT").
2. Use full therapeutic-dose enoxaparin for the DVT (1 mg/kg SC q12h or 1.5 mg/kg SC daily, per Washington Manual of Medical Therapeutics dosing table), adjusted for renal function.
3. Reassess whether aspirin can be temporarily held or minimized (e.g., low-dose 81 mg rather than higher doses) if the cardiac/vascular indication allows.
4. Watch closely for bleeding (GI, mucosal, access-site), consider GI protection (PPI) if risk factors for GI bleed are present, and monitor platelet counts if prolonged (HIT risk with LMWH).
5. If there is no separate indication for aspirin, it should be stopped, not combined with enoxaparin, because it doesn't improve DVT outcomes and only adds bleeding risk.

Evidence check

Causes of Deep Vein Thrombosis (DVT)

1. Venous Stasis

• Prolonged immobility (bed rest, long-haul travel, hospitalization, paralysis)
• Surgery (especially orthopedic, abdominal, pelvic) and general anesthesia
• External venous compression - tumors, May-Thurner syndrome (left common iliac vein compressed by right iliac artery), iliac artery aneurysm
• Heart failure (reduced venous return)
• Varicose veins

2. Hypercoagulable States

• Factor V Leiden mutation (most common inherited cause)
• Prothrombin gene mutation (G20210A)
• Protein C deficiency
• Protein S deficiency
• Antithrombin III deficiency
• Homocystinuria (rare, causes early-onset arterial and venous thrombosis)

• Malignancy (active cancer is one of the strongest acquired risk factors)
• Pregnancy and the postpartum period
• Estrogen-containing medications - oral contraceptives, hormone replacement therapy (about 3x risk)
• Antiphospholipid syndrome (lupus anticoagulant, anticardiolipin, β2-glycoprotein-1 antibodies)
• Heparin-induced thrombocytopenia (HIT)
• Nephrotic syndrome
• Disseminated intravascular coagulation (DIC)
• Infection/sepsis and systemic inflammation
• Myeloproliferative disorders (JAK2 mutation) and paroxysmal nocturnal hemoglobinuria - especially if thrombosis occurs in unusual locations (portal, mesenteric, cavernous sinus veins)
• Trauma and surgery (release of tissue factor from damaged tissue drives a strong procoagulant state)
• Inflammatory bowel disease

3. Endothelial (Vessel Wall) Injury

• Trauma (fractures, especially lower extremity and hip)
• Surgery, particularly orthopedic procedures (hip/knee arthroplasty, arthroscopy)
• Central venous catheters or IV lines
• Prior DVT (scarring/damage from previous clot)
• IVC filter placement

Other well-established risk factors (compounding the triad)

• Age >60-70 years (risk rises sharply, up to 10x over age 70)
• Obesity (BMI >29-30)
• Smoking
• Female sex
• Diabetes and hypertension (roughly 2x risk)
• Complex/prolonged surgical procedures

Provoked vs. Unprovoked

• Provoked - a clear precipitating factor is identifiable (surgery, trauma, immobilization, estrogen use, pregnancy)
• Unprovoked - no identifiable cause; these carry a higher recurrence risk (8-10% per year after stopping anticoagulation) regardless of whether an inherited thrombophilia is found - Washington Manual of Medical Therapeutics, p. 775.

Recent evidence context

Diagnosis: Paget-Schroetter Syndrome (Effort Thrombosis)

Underlying Cause: Venous Thoracic Outlet Compression

1. Repetitive compression injury of the subclavian vein in the costoclavicular space during exertional arm movement
2. Progressive venous scarring and focal stenosis develop over time from repeated mechanical trauma
3. The body compensates by forming a collateral venous network
4. As fibrosis progresses, outflow becomes increasingly compromised
5. Complete thrombosis is finally triggered by an episode of vigorous activity (the "effort" in effort thrombosis) that further narrows or occludes the already-scarred vein - Fischer's Mastery of Surgery, p. 3871.

Contributing/Predisposing Anatomic Factors

• Cervical rib (extra rib arising from C7)
• Anomalous or hypertrophied first rib
• Myofascial or fibrous bands in the thoracic outlet
• Muscular subclavius or scalene hypertrophy (common in athletes/weightlifters who build up the shoulder girdle musculature)

Why This Differs from "Typical" DVT

Important Differential to Exclude

• Indwelling central venous catheter or pacemaker leads
• Underlying thrombophilia (inherited: Factor V Leiden, protein C/S deficiency; less likely at this age but worth screening if recurrent/unprovoked)
• Malignancy (rare at 15, but idiopathic upper-extremity DVT should prompt evaluation for occult malignancy in general practice) - Sabiston Textbook of Surgery, p. 2417.

Standard Management Path (for context)